Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende

Die Highlights vom Kongress des American College of Cardiology 2024

Im April diskutierten die Herz-Kreislauf-Spezialisten aus der ganzen Welt auf dem  Kongress des American College of Cardiology (ACC) u.a. neue Therapieansätze bei akutem Myokardinfarkt, koronarer Herzerkrankung, kardiogenem Schock oder Aortenklappenstenose. In unserem Kongress-Dossier haben wir für Sie Berichte über die „Late-Breaking Trials“ und andere wichtige Studien zusammengestellt. 
Erweiterte Suche
Anmelden
nach oben
Drugs
Erschienen in: Drugs 7/2016

01.05.2016 | Review Article

Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia

verfasst von: Dhanya Vijayakumar, Joseph Jankovic

Erschienen in: Drugs | Ausgabe 7/2016

Einloggen, um Zugang zu erhalten

Abstract

Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
Literatur
1.
Loonen AJMAJ. New insights into the mechanism of drug-induced dyskinesia. CNS spectrums. 2013;18(1):15.CrossRefPubMed
2.
Walters AS, McHale D, Sage JI, Hening WA, Bergen M. A blinded study of the suppressibility of involuntary movements in Huntington’s chorea, tardive dyskinesia, and L-dopa-induced chorea. Clin Neuropharmacol. 1990;13(3):236–40.CrossRefPubMed
3.
Waln O, Jankovic J. An update on tardive dyskinesia: from phenomenology to treatment. Tremor Other Hyperkinet Mov. 2013;12(3):03–161.
4.
5.
Cloud LJ, Zutshi D, Factor SA. Tardive dyskinesia: therapeutic options for an increasingly common disorder. Neurotherapeutics. 2014;11(1):166–76.CrossRefPubMedPubMedCentral
6.
7.
Anand VS, Dewan MJ. Withdrawal-emergent dyskinesia in a patient on risperidone undergoing dosage reduction. Ann Clin Psychiatry. 1996;8(3):179–82.CrossRefPubMed
8.
American Psychiatric Association. Medication-induced movement disorders and other adverse effects of medication. Diagnostic and statistical manual of mental disorders, Fifth edn: American Psychiatric Association; 2013.
9.
Mejia NI, Jankovic J. Tardive dyskinesia and withdrawal emergent syndrome in children. Expert Rev Neurother. 2010;10(6):893–901.CrossRefPubMed
10.
Karama S, Lal S. Tardive dyskinesia following brief exposure to risperidone–a case study. Eur Psychiatry. 2004;19(6):391–2.CrossRefPubMed
11.
O’Brien A. Comparing the risk of tardive dyskinesia in older adults with first-generation and second-generation antipsychotics: a systematic review and meta-analysis. Int J Geriatr Psychiatry. 2015. doi:10.​1002/​gps.​4399
12.
Novick D, Haro JM, Bertsch J, Haddad PM. Incidence of extrapyramidal symptoms and tardive dyskinesia in schizophrenia: thirty-six-month results from the European schizophrenia outpatient health outcomes study. J Clin Psychopharmacol. 2010;30(5):531–40.CrossRefPubMed
13.
Aquino CC, Lang AE. Tardive dyskinesia syndromes: current concepts. Parkinsonism Relat Disord. 2014;20(Suppl 1):S113–7.CrossRefPubMed
14.
Kiriakakis V, Bhatia KP, Quinn NP, Marsden CD. The natural history of tardive dystonia. A long-term follow-up study of 107 cases. Brain J Neurol. 1998;121(Pt 11):2053–66.CrossRef
15.
Correll CU, Schenk EM. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6.CrossRefPubMed
16.
Jankovic J. Bradley’s Neurology in Clinical Practice 2012.
17.
Lehosit JBP, Fermina, Dhanya V, Leslie C. Tardive Dyskinesia. Wiley: Chichester. 2015.
18.
Correll CUCU. Tardive dyskinesia and new antipsychotics. Curr Opin Psychiatry. 2008;21(2):151–6.CrossRefPubMed
19.
Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry. 2004;161(3):414–25.CrossRefPubMed
20.
Kinon BJ, Kollack-Walker S, Jeste D, Gupta S, Chen L, Case M, et al. Incidence of tardive dyskinesia in older adult patients treated with olanzapine or conventional antipsychotics. J Geriatr Psychiatry Neurol. 2015;28(1):67–79.CrossRefPubMed
21.
Lee PE, Sykora K, Gill SS, Mamdani M, Marras C, Anderson G, et al. Antipsychotic medications and drug-induced movement disorders other than parkinsonism: a population-based cohort study in older adults. J Am Geriatr Soc. 2005;53(8):1374–9.CrossRefPubMed
22.
Rosenheck RA. Evaluating the cost-effectiveness of reduced tardive dyskinesia with second-generation antipsychotics. Br J Psychiatry J Mental Sci. 2007;191:238–45.CrossRef
23.
Rosenheck R, Cramer J, Xu W, Thomas J, Henderson W, Frisman L, et al. A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. N Engl J Med. 1997;337(12):809–15.CrossRefPubMed
24.
Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA. 2003;290(20):2693–702.CrossRefPubMed
25.
Obeso JA. The Movement Disorders journal 2016 and onward. Mov Disord. 2016;31(1):1–2 (Epub 2016/01/11).CrossRefPubMed
26.
Adrianzen C, Arango-Davila C, Araujo DM, Ruiz I, Walton RJ, Dossenbach M, et al. Relative association of treatment-emergent adverse events with quality of life of patients with schizophrenia: post hoc analysis from a 3-year observational study. Hum Psychopharmacol. 2010;25(6):439–47.CrossRefPubMed
27.
28.
Kapur S, Seeman P. Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis. Am J Psychiatry. 2001;158(3):360–9.CrossRefPubMed
29.
Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553–9.CrossRefPubMed
30.
Standaert DG, Galanter JM. Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy: Lippincott Williams & Wilkins, 2008.
31.
Pena MS, Yaltho TC, Jankovic J. Tardive dyskinesia and other movement disorders secondary to aripiprazole. Mov Disord. 2011;26(1):147–52.CrossRefPubMed
32.
Casey DE. Tardive dyskinesia: pathophysiology and animal models. J Clin Psychiatry. 2000;4:5–9.
33.
Corson PW, Nopoulos P, Miller DD, Arndt S, Andreasen NC. Change in basal ganglia volume over 2 years in patients with schizophrenia: typical versus atypical neuroleptics. Am J Psychiatry. 1999;156(8):1200–4.PubMed
34.
Ogawa T, Nagao T, Kashiwabara K, Fujiwara Y, Harada T, Otsuki S. Tardive dyskinesia and neurotransmitters: effects of sodium valproate, cyproheptadine, oxypertine, hydroxyzine pamoate and Ca-hopantenate on monoamine metabolites, cyclic nucleotides and gamma-aminobutyric acid in human cerebrospinal fluid. Clin Ther. 1984:1–17.
35.
Mizuno Y. Parkinson’s Disease: CRC Press, 2012.
36.
Aia PG, Revuelta GJ, Cloud LJ, Factor SA. Tardive dyskinesia. Curr Treat Options Neurol. 2011;13(3):231–41.CrossRefPubMed
37.
Glazer WM, Morgenstern H, Schooler N, Berkman CS, Moore DC. Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. Br J Psychiatry. 1990;157:585–92.CrossRefPubMed
38.
Modestin J, Wehrli MV, Stephan PL, Agarwalla P. Evolution of neuroleptic-induced extrapyramidal syndromes under long-term neuroleptic treatment. Schizophr Res. 2008;100(1–3):97–107.CrossRefPubMed
39.
Fernandez HH, Krupp B, Friedman JH. The course of tardive dyskinesia and parkinsonism in psychiatric inpatients: 14-year follow-up. Neurology. 2001;56(6):805–7.CrossRefPubMed
40.
Viguera AC, Baldessarini RJ, Hegarty JD, van Kammen DP, Tohen M. Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Arch Gen Psychiatry. 1997;54(1):49–55.CrossRefPubMed
41.
Bhidayasiri R, Fahn S, Weiner WJ, Gronseth GS, Sullivan KL, Zesiewicz TA. Evidence-based guideline: treatment of tardive syndromes: report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2013;81(5):463–9.CrossRefPubMed
42.
Hazari N, Kate N, Grover S. Clozapine and tardive movement disorders: a review. Asian J Psychiatr. 2013;6(6):439–51.CrossRefPubMed
43.
Jankovic J, Clarence-Smith K. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders. Expert Rev Neurother. 2011;11(11):1509–23.CrossRefPubMed
44.
Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry. 1999;156(8):1279–81.PubMed
45.
Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry. 1973;130(4):479–83.PubMed
46.
Chen JJ, Ondo WG, Dashtipour K, Swope DM. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature. Clin Ther. 2012;34(7):1487–504.CrossRefPubMed
47.
Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology. 1988;38(3):391–4.CrossRefPubMed
48.
Shen V, Clarence-Smith K, Hunter C, Jankovic J. Safety and efficacy of tetrabenazine and use of concomitant medications during long-term, open-label treatment of chorea associated with huntington’s and other diseases. Tremor Other Hyperkinet Mov. 2013;22(3):03–191.
49.
Kenney C, Hunter C, Mejia N, Jankovic J. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol. 2006;29(5):259–64 (Epub 2006/09/09).CrossRefPubMed
50.
Stamler D, Bradbury M, Brown F, editors. The pharmacokinetics and safety of deuterated-tetrabenazine. 65th AAN Annual Meeting; 2013; San Diego: Neurology.
51.
Muller T. Valbenazine granted breakthrough drug status for treating tardive dyskinesia. Expert opinion on investigational drugs. 2015;24(6):737–42 (Epub 2015/03/27).CrossRefPubMed
52.
O’Brien CF, Jimenez R, Hauser RA, Factor SA, Burke J, Mandri D, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: A randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30(12):1681–7.CrossRefPubMed
53.
Thaker GK, Nguyen JA, Strauss ME, Jacobson R, Kaup BA, Tamminga CA. Clonazepam treatment of tardive dyskinesia: a practical GABAmimetic strategy. Am J Psychiatry. 1990;147(4):445–51.CrossRefPubMed
54.
Woods SW, Saksa JR, Baker CB, Cohen SJ, Tek C. Effects of levetiracetam on tardive dyskinesia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2008;69(4):546–54.CrossRefPubMed
55.
Libov I, Miodownik C, Bersudsky Y, Dwolatzky T, Lerner V. Efficacy of piracetam in the treatment of tardive dyskinesia in schizophrenic patients: a randomized, double-blind, placebo-controlled crossover study. J Clin Psychiatry. 2007;68(7):1031–7.CrossRefPubMed
56.
Zhang WF, Tan YL, Zhang XY, Chan RC, Wu HR, Zhou DF. Extract of Ginkgo biloba treatment for tardive dyskinesia in schizophrenia: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2011;72(5):615–21.CrossRefPubMed
57.
Schrodt GR Jr, Wright JH, Simpson R, Moore DP, Chase S. Treatment of tardive dyskinesia with propranolol. J Clin Psychiatry. 1982;43(8):328–31.PubMed
58.
Waln OO. Zolpidem improves tardive dyskinesia and akathisia. Mov Disord. 2013;28(12):1748–9.CrossRefPubMed
59.
Yasui-Furukori N, Kikuchi A, Katagai H, Kaneko S. The effects of electroconvulsive therapy on tardive dystonia or dyskinesia induced by psychotropic medication: a retrospective study. Neuropsychiatr Dis Treat. 2014;10:1209–12.CrossRefPubMedPubMedCentral
60.
Peng LY, Lee Y, Lin PY. Electroconvulsive therapy for a patient with persistent tardive dyskinesia: a case report and literature review. J Ect. 2013;29(3).
61.
Malek-Ahmadi P, Weddige RL. Tardive Dyskinesia and Electroconvulsive Therapy. Convuls Ther. 1988;4(4):328–31.PubMed
62.
Hennings JM, Krause E, Botzel K, Wetter TC. Successful treatment of tardive lingual dystonia with botulinum toxin: case report and review of the literature. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(5):1167–71.CrossRefPubMed
63.
Beckmann YY, Secil Y, Saka S, Kuserli A, Ciftci Y. Treatment of intractable tardive lingual dyskinesia with botulinum toxin. J Clin Psychopharmacol. 2011;31(2):250–1 (Epub 2011/03/03).CrossRefPubMed
64.
Rapaport A, Sadeh M, Stein D, Levine J, Sirota P, Mosheva T, et al. Botulinum toxin for the treatment of oro-facial-lingual-masticatory tardive dyskinesia. Mov Disord. 2000;15(2):352–5.CrossRefPubMed
65.
Tschopp L, Salazar Z, Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol. 2009;32(3):165–6.CrossRefPubMed
66.
van Harten PN, Hovestadt A. Botulinum toxin as a treatment for tardive dyskinesia. Mov Disord. 2006;21(8):1276–7.CrossRefPubMed
67.
Spindler MA, Galifianakis NB, Wilkinson JR, Duda JE. Globus pallidus interna deep brain stimulation for tardive dyskinesia: case report and review of the literature. Parkinsonism Relat Disord. 2013;19(2):141–7.CrossRefPubMed
68.
Kefalopoulou Z, Paschali A, Markaki E, Vassilakos P, Ellul J, Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand. 2009;119(4):269–73.CrossRefPubMed
69.
Damier P, Thobois S, Witjas T, Cuny E, Derost P, Raoul S, et al. Bilateral deep brain stimulation of the globus pallidus to treat tardive dyskinesia. Arch Gen Psychiatry. 2007;64(2):170–6.CrossRefPubMed
70.
Sun B, Chen S, Zhan S, Le W, Krahl SE. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl. 2007;97(Pt 2):207–14.CrossRefPubMed
71.
Zhang JG, Zhang K, Wang ZC, Ge M, Ma Y. Deep brain stimulation in the treatment of secondary dystonia. Chin Med J. 2006;119(24):2069–74.PubMed
72.
Lorberboym M, Treves TA, Melamed E, Lampl Y, Hellmann M, Djaldetti R. [123I]-FP/CIT SPECT imaging for distinguishing drug-induced parkinsonism from Parkinson’s disease. Mov Disord. 2006;21(4):510–4.CrossRefPubMed
Metadaten
Titel
Drug-Induced Dyskinesia, Part 2: Treatment of Tardive Dyskinesia
verfasst von
Dhanya Vijayakumar
Joseph Jankovic
Publikationsdatum
01.05.2016
Verlag
Springer International Publishing
Erschienen in
Drugs / Ausgabe 7/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI
https://doi.org/10.1007/s40265-016-0568-1

Weitere Artikel der Ausgabe 7/2016

Drugs 7/2016 Zur Ausgabe

Adis Drug Evaluation

Idebenone: A Review in Leber’s Hereditary Optic Neuropathy

Review Article

Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia

Review Article

Naphthoquine: An Emerging Candidate for Artemisinin Combination Therapy

Current Opinion

Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century

Current Opinion

Ivabradine: Cardioprotection By and Beyond Heart Rate Reduction

AdisInsight Report

Obiltoxaximab: First Global Approval